Ruby Khoury.

Ruby Khoury, MD


  • Physician, Division of Bone Marrow Transplantation and Immune Deficiency
  • Instructor, UC Department of Pediatrics

About

Services and Specialties

Cancer and Blood Diseases

Research Areas

Bone Marrow Transplantation and Immune Deficiency

Additional Languages

Arabic, French

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Age Impacts Risk of Mixed Chimerism Following Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Non-Severe Combined Immune Deficiency Inborn Errors of Immunity. Fitch, T; Lane, A; McDonnell, J; Bleesing, J; Jordan, M; Kumar, A; Khandelwal, P; Khoury, R; Marsh, R; Chandra, S. Transplantation and cellular therapy. 2024; 30:101.e1-101.e12.

Viral specific T cell therapy in kidney transplant recipients - A single-center experience. Anand, M; Nysather, J; McGraw, G; Apewokin, S; Khoury, R; Grimley, MS; Bumb, S; Govil, A. Transplant Infectious Disease. 2023; 25:e14179.

Viral-specific T cells for Cytomegalovirus retinitis following hematopoietic stem cell transplantation: A success story. Montiel-Esparza, R; Michalak, SM; Le, AH D; Or, C; Nguyen, QD; Khoury, R; Grimley, MS; Bertaina, A; Klinger, E; Shah, AJ; et al. Pediatric Blood and Cancer. 2023; 70:e30429.

Post CAR T-cell therapy outcomes and management in HSCT-naive patients: a single-center experience. Phillips, CL; Krupski, C; Khoury, R; Dandoy, CE; Nelson, AS; Galletta, TJ; Faulhaber, A; Davies, SM; Rubinstein, JD. 2023; 2:1151744.

Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel. Galletta, TJ; Rubinstein, JD; Krupski, C; Nelson, AS; Khoury, R; Dandoy, CE; Davies, SM; Phillips, CL. Pediatric Blood and Cancer. 2023; 70:e30271.

Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults. Galletta, TJ; Lane, A; Lutzko, C; Leemhuis, T; Cancelas, JA; Khoury, R; Wang, YZ M; Hanley, PJ; Keller, MD; Bollard, CM; et al. Transplantation and cellular therapy. 2023; 29:305-310.

The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL. Rubinstein, JD; Breese, EH; Krupski, MC; O'Brien, MM; Dandoy, CE; Mizukawa, B; Khoury, R; Norris, RE; Davies, SM; Phillips, CL. Transplantation and cellular therapy. 2023; 29:311.e1-311.e7.

Head and Neck Cancer Susceptibility and Metabolism in Fanconi Anemia. Chihanga, T; Vicente-Muñoz, S; Ruiz-Torres, S; Pal, B; Sertorio, M; Andreassen, PR; Khoury, R; Mehta, P; Davies, SM; Lane, AN; et al. Cancers. 2022; 14:2040.

477 Availability of Donor Derived Patient Specific Virus-Specific T-Cells (VSTs) Is Not Associated with Differences in Outcomes As Compared to Frontline Administration of Third Party Vsts for the Management of Viral Infections after Pediatric Hematopoietic Stem Cell Transplant. Galletta, TJ; Lane, A; Lutzko, CM; Leemhuis, T; Cancelas, JA; Khoury, R; Wang, YM; Hanley, PJ; Keller, MD; Bollard, CM; et al. Transplantation and cellular therapy. 2022; 28:s374-s375.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

4.6
Overall Patient Rating